Clearpoint Neuro Inc (CLPT)vsNovartis AG ADR (NVS)
CLPT
Clearpoint Neuro Inc
$11.18
+8.12%
HEALTHCARE · Cap: $353.24M
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 152933% more annual revenue ($56.58B vs $36.97M). NVS leads profitability with a 23.9% profit margin vs -69.1%. CLPT appears more attractively valued with a PEG of 0.61. NVS earns a higher WallStSmart Score of 51/100 (C-).
CLPT
Hold37
out of 100
Grade: F
NVS
Buy51
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+13.1%
Fair Value
$15.39
Current Price
$11.18
$4.21 discount
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 34.0% year-over-year
Growing faster than its price suggests
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
Trading at 11.8x book value
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
Comparative Analysis Report
WallStSmart ResearchBull Case : CLPT
The strongest argument for CLPT centers on Revenue Growth, PEG Ratio. Revenue growth of 34.0% demonstrates continued momentum. PEG of 0.61 suggests the stock is reasonably priced for its growth.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : CLPT
The primary concerns for CLPT are Price/Book, EPS Growth, Market Cap. Debt-to-equity of 2.25 is elevated, increasing financial risk.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Key Dynamics to Monitor
CLPT profiles as a hypergrowth stock while NVS is a declining play — different risk/reward profiles.
CLPT carries more volatility with a beta of 1.18 — expect wider price swings.
CLPT is growing revenue faster at 34.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 37/100), backed by strong 23.9% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Clearpoint Neuro Inc
HEALTHCARE · MEDICAL DEVICES · USA
ClearPoint Neuro, Inc. is a medical device company primarily in the United States. The company is headquartered in Irvine, California.
Visit Website →Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?